September 2026: Ispire Technology Joint Venture Unveils IKE 2.0 to Drive Continuous Compliance Beyond the Point of Sale
IKE Tech, a Joint Venture between Ispire Technology, Touch Point Worldwide (d/b/a Berify) and Chemular, has launched IKE 2.0 – a next-generation compliance infrastructure platform designed to maintain continuous accountability across the entire lifecycle of regulated products. Traditional regulatory checks stop at the retail cash register, leaving manufacturers and authorities with zero post-sale visibility into product authenticity, user eligibility, or local regulatory adherence. IKE 2.0 closes this critical compliance gap by linking verified user identity, authenticated hardware, and real-time policy controls directly at the point of use.
Protected by 11 issued patents, the platform connects four core infrastructure layers:
1. Person Layer: Uses on-device biometric processing to generate secure Human Identity Tokens (HIT), protecting consumer privacy while satisfying SOC 2 Type II, GDPR, and CCPA standards.
2. Product Layer: Integrates low-cost NFC tags or Bluetooth chips for end-to-end supply chain traceability and anti-counterfeiting.
3. Policy Layer: Enforces location- and age-based access rules, enabling features like automatic geofencing around restricted zones.
4. Intelligence Layer: Delivers real-time operational telemetry and analytics for compliance oversight.
The launch builds on IKE Tech’s regulatory progress with the U.S. FDA, including the 2025 acceptance for review of its standalone PMTA for age-verification technology. In controlled human factors testing, the technology achieved 100% effectiveness in blocking underage device activation while maintaining a 91% adult ease-of-use rating.
By combining Ispire’s hardware manufacturing expertise with IKE Tech’s continuous compliance architecture, Ispire aims to provide global brand partners with a fully compliant, future-proof hardware ecosystem. While initially deployed in the nicotine sector, the modular technology is designed for seamless expansion into cannabis hardware, pharmaceuticals, and other age-restricted consumer categories.
September 2026: Ispire Technology Reports Fourth Quarter and Fiscal Year 2026 Results
Ispire Technology reported its financial results for the fourth quarter and full fiscal year ended June 30, 2026, highlighting a significant turnaround in the fourth quarter despite full-year revenue declines. In Q4 FY2026, revenue reached $26.7 million, marking a 33% increase year-over-year from $20.1 million in Q4 FY2025 and a 43% sequential increase from $18.7 million in the previous quarter. Gross profit for the quarter was $1.7 million with a gross margin of 6.3%, down from 12.3% in the prior-year period due to inventory impairments. Operating expenses, excluding credit losses, dropped 28.6% year-over-year to $6.0 million, reflecting a leaner cost structure. Legacy credit loss expenses stood at $9.2 million compared to $9.7 million a year earlier. The net loss for the quarter narrowed to $13.8 million, or $0.24 per share, compared to $14.8 million in Q4 FY2025, while the Adjusted EBITDA loss improved to $2.3 million from a loss of $4.4 million.
For the full fiscal year 2026, total revenue was $96.0 million, down 24.7% from $127.5 million in fiscal 2025, driven primarily by lower U.S. cannabis vaping hardware sales, reduced European vaping product sales, and a slight dip in non-China Asia-Pacific markets. Full-year gross margin contracted to 12.8% from 17.8% due to product mix shifts and inventory provisions. The full-year net loss improved to $33.2 million, or $0.58 per share, compared to $39.2 million, or $0.69 per share, in the previous fiscal year. Operating cash burn improved drastically by $6.8 million, with net cash used in operating activities narrowing to just $0.57 million from $7.4 million in FY2025. The company ended the fiscal year with $19.3 million in cash and cash equivalents.
| Catalyst | Timeline | Opportunity |
| Malaysia Manufacturing | Now | ~$73B global vape market; 25% tariff advantage over China for exports to US |
| Vapor ODM | July 2026 / 2027 | Mid-sized brands in 2026; large brand partnerships in 2027 |
| Age-Gating (IKE Tech) | 2027+ | ~$50-70B US flavored vape market currently locked; ~6B devices/year US TAM |
| G-Mesh Technology | 2027+ | $24B+ legal global vape market; licensing discussions with big tobacco underway |
Strategically, Ispire scaled up its company-owned manufacturing facilities in Malaysia, which have begun production of vapor products and nicotine pouches, capturing strong interest from Chinese brands seeking manufacturing diversification outside of China as well as major global tobacco companies. The company is also advancing commercialization steps for its proprietary age-gating and G-Mesh technologies through its IKE Tech joint venture, with newer iterations like IKE 2.0 slated for rollout. Management emphasized that the company has reached an operational inflection point by successfully cutting overhead, addressing legacy balance sheet issues, and working through receivables, with expectations that remaining receivable write-offs will be largely cleared during fiscal 2027.
May 2026: Ispire Enters Fast-Growing Nicotine Pouch Market via Strategic Joint Venture with Jincheng Pharma
Ispire Technology has announced a strategic joint venture with Jincheng Pharma to enter the rapidly expanding nicotine pouch market, marking a significant diversification beyond its core vaping hardware business. Under the agreement, Jincheng Pharma will provide pharmaceutical-grade manufacturing capabilities, technical expertise, and nicotine pouch materials, while Ispire contributes its global distribution network, precision dosing technology, and regulatory infrastructure. The partnership is designed to accelerate commercialization and build a scalable position in the oral nicotine segment.
Jincheng Pharma is a diversified pharmaceutical company with 3,800 employees and more than 30 affiliated companies worldwide. The company is engaged in the research, development, production, and commercialization of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), finished pharmaceutical products, and health-related products.
The joint venture is positioned as a key step in Ispire’s broader strategy to expand its presence across next-generation nicotine categories, leveraging its technology platform and compliance capabilities to compete in an increasingly globalized and regulated market.
May 2026: Ispire Technology Q3 2026 – Malaysia Expansion, Vapor ODM Launch, and IKE Tech Position Long-Term Growth Strategy
Ispire Technology reported Q3 2026 results for the three months ended March 31, 2026, reflecting continued business stabilization amid the company’s strategic transition away from lower-quality cannabis revenue toward regulated nicotine delivery and compliance-focused technologies. Cash increased sequentially to $18 million, while several near-term and longer-term growth initiatives continued to advance.
The company’s Malaysia manufacturing facility became operational during the quarter, providing an estimated 25% tariff advantage relative to China-based vape production. Supply of nicotine pouches to global customers commenced in April 2026, while the company’s vapor ODM platform is scheduled to launch in July 2026 targeting mid-sized brands, with larger brand partnerships expected in 2027.
Looking further ahead, management highlighted proprietary age-gating technology being developed through IKE Tech, which could support future regulatory-compliant flavored vape commercialization in the U.S. The company also stated that its G-Mesh glass technology is attracting interest from major tobacco companies.
Growth Catalysts & Addressable Market:
Financially, revenue declined to $18.7 million from $26.2 million in Q3 2025 and $20.3 million in Q2 2026. The year-over-year decline primarily reflects the company’s strategic shift away from lower-quality cannabis business. Sequentially, revenue declined 8%, which management described as the smallest second-to-third quarter decline in company history despite seasonal disruption from Chinese New Year-related factory shutdowns.
Gross profit declined to $2.0 million from $4.8 million in Q3 2025 and $3.5 million in Q2 2026. Gross margin fell to 10.7% from 18.2% a year earlier, primarily due to approximately $2.2 million in one-time product returns associated with legacy cannabis customers with whom Ispire has ceased doing business.
Total operating expenses excluding bad debt expense declined 36% year-over-year to $5.9 million, compared to $9.3 million in Q3 2025, and decreased modestly from $6.1 million in Q2 2026. Bad debt expense totaled $5.6 million, down $0.5 million year-over-year but up $1.4 million sequentially.
Net loss was $9.5 million, or ($0.17) per share, compared to a net loss of $10.9 million, or ($0.19) per share, in Q3 2025, and a net loss of $6.6 million in Q2 2026. As of March 31, 2026, Ispire reported cash of $18.0 million and working capital of $0.9 million.
February 2025: Ispire Technology Reports Q2 2026 Financial Results
– Revenue: down 51.4% to $20.3 million due to the strategic shift away from lower quality cannabis customers
– Gross profit: down 54.5% to $3.5 million (gross margin down 1.4pp to 17.1%, primarily due to changes in product mix)
– Total operating expenses: down 31.8% to $10.3 million, highlighting the impact of efficiency initiatives
– Net loss: narrowed down to $6.6 million ($0.12 per share) from $8.0 million ($0.14 per share) in Q2 2025
– Yearlong cost cutting and focus on higher-quality customers (i.e. net accounts receivable down 19.5% to $37.9 million) set the foundation for top line growth, consistent cash flows and bottom-line improvement in the quarters to come
– Ramp up of manufacturing capabilities in Malaysia. Potential licensing and partnership opportunities explored for the proprietary G-Mesh technology. Global regulatory engagement by IKE Tech JV to support the broader adoption of age-gating technology as a safer industry standard.
– Liquidity (at December 31, 2025): $17.6 million cash and $3.5 million working capital
September 2025: Ispire Technology Reports FY25 Financial Results
– Revenue: down -16% to $127.5 million (due to business realignment towards nicotine, while moving away from cannabis customers)
– Gross profit: down -24% to $22.6 million (gross margin down -1.8pp 17.8% due to revenue decline)
– Total operating expenses: up +30% to $60.5 million (annual payroll cut of $10.2 million and reduction in R&D expenses more than offset by the ramp up of marketing activities and an increase in expected credit loss on accounts receivables)
– Accounts receivable: down -21% to $47.0 million (focus on strengthening collections)
– Net loss: up +165% to $39.2 million (EPS: -$0.69 in FY25 vs. -$0.27 in FY24)
– Cash and cash equivalents: $24.4 million (working capital: $0.4 million)
Key Highlights:
– 2025 marks a pivotal period in Ispire’s strategic transformation from the cannabis industry toward the higher-value nicotine sector with focus on long-term partnerships
– Investments in breakthrough technologies, including IKE Tech and our G-Mesh technology, gaining significant traction with major tobacco companies as these innovations move through the regulatory approval process. Waiting for the outcome of the PMTA submission for blockchain-based age verification technology filed by IKE Tech LLC. Preparing PMTA submissions for 4 distinct flavored vape products featuring integrated IKE Tech age-verification technology
– International nicotine ODM (Original Design Manufacturer) gaining significant momentum with $18 million order backlog after a slower than expected start
May 2025: Ispire Technology Receives Interim License for Nicotine Manufacturing in Malaysia
Ispire Technology received an interim license from the Malaysian Government for the manufacturing of nicotine products. This is the first and only nicotine manufacturing license issued in Malaysia. Ispire expects the final license to be approved in the coming months.
Ispire will increase the production capacity in the Malaysian facility from six lines to 80 lines. By diversifying the production base (outside China), Ispire aims to mitigate the impact of geopolitical factors (tariffs) on import/export prices. All manufacturing activities at Ispire’s Johor, Malaysia facility are exclusively for export purposes and no production or distribution of any nicotine- or cannabis-containing liquids or gels will take place within Malaysia and for export. The facility produces semi-finished vaporizer hardware only and Ispire products integrate blockchain-based age-gating and geo-fencing technology, ensuring use is restricted to adults and compliant areas. Ispire’s patented technology has been submitted for review by the U.S. Food and Drug Administration.
While the facility is capable of producing certified components, no medical devices are currently manufactured. Any future activity in medical devices would follow a comprehensive regulatory review. With an investment target exceeding $50 million, Ispire aims to position the Malaysian facility as a premier manufacturing hub in Southeast Asia.
May 2025: Ispire Technology Announces the Appointment of Jie Yu as the CFO
Ispire Technology announced the appointment of Jie “Jay” Yu, formerly Vice President of Finance, as the new Chief Financial Officer (CFO) effective immediately. At the same time, Ispire re-iterated its commitment to further streamline the overall operations; the Company reduced its workforce and ended several contractor agreements, resulting in a reduction of $3.6 million in annual payroll in May 2025. Ispire will also cut up to an additional $6.6 million in operating expenses over the next three months, bringing the total estimated reduction in annual operating expenses to $10.2 million in FY25. Ispire aims to become a global provider of precision dosing vaping technology while delivering value to shareholders through long-term sustainable and profitable growth.
May 2025: Ispire-founded JV Files a Component PMTA for its Bluetooth Chip
Ispire Technology announced that IKE Tech – a joint venture (JV) comprised of Ispire Technology, Touch Point Worldwide Inc. d/b/a Berify and Chemular – filed a component Pre-Market Tobacco Product Application (PMTA) and Tobacco Product Master File (TPMF) with the U.S. Food and Drug Administration (FDA) for its Bluetooth Low Energy (BLE) System-on-a-Chip.
This is the first PMTA submission for a standalone, interoperable, blockchain-enabled age-verification component, designed for universal integration across all vape devices. Unlike traditional systems that verify age once at purchase, IKE’s platform requires continuous, real-time verification for device access. IKE formally requested an expedited review of the application, citing the system’s potential to enhance public health. In the Human Factors Validation Study submitted with the PMTA, the technology achieved 100% effectiveness in preventing device activation by underage users, 100% accuracy in demographic verification, 91% user satisfaction with app simplicity and functionality and less than 1% user error rates (i.e. high ease of use). The submission builds on a pre-PMTA meeting with the U.S. FDA in Q4 2024, during which regulators confirmed their willingness to evaluate component-based PMTAs.
By setting a new standard for youth prevention and device security, IKE BLE technology could serve as a key enabler for expanded regulatory pathways for flavored vapes (i.e. offering adult smokers more choices while eliminating youth access). Ispire aims to benefit from both commercial sales of the regulatory-compliant IKE BLE chip and integration of the technology to own devices.
August 2024: Ispire Signs Licensing Agreement with Hidden Hills
Ispire Technology’s subsidiary, Aspire North America LLC signed an exclusive 30-year global licensing agreement with Hidden Hills Club. Under the agreement, Ispire will globally manufacture, distribute and commercialize Hidden Hills nicotine products. United Arab Emirates and South Africa are determined as the first launch markets, to be followed by the United Kingdom and European Union over the next months.
Earlier this year, Ispire and Hidden Hills Club teamed up to launch Ispire’s dual-tank SWTCH ONE with a variety of select cannabis and hemp oils from Hidden Hills as an all-in-one cannabis and hemp vaping experience under the brand name, Hidden Hills & Friends. The extended partnership aims to expand the Hidden Hills’ popularity as a lifestyle brand – encompassing apparel, clothing and cannabis and hemp products – to the global nicotine products market.
April 2023: Ispire Technology Goes Public
Ispire first downsized its proposed IPO by 50% to $21Mn (3Mn shares x $7/share) in late-March. It further reduced its offering by 0.3Mn shares and went public on April 4, 2023 under the ticker ISPR1
– $19Mn raised by offering 2.7Mn shares at $7
– First day of trading: $7.01 day low, $9.38 day high
Proceeds from the IPO will be used for:
– manufacturing operations development in Vietnam and California, USA (35%)
– R&D, which include efforts to develop new products and vaping technology (25%)
– marketing and promotion (20%)
– G&A and working capital (20%).
Ispire sells (Aspire) branded nicotine and cannabis vape devices worldwide (ex-China and Russia)2. It ceased marketing nicotine vapes in the US, stating the high marketing and regulatory costs.
